Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alector, Inc.ALEC · Entity 6051 | Director | June 17, 2026 | June 17, 2026 |
| Myovant Sciences Ltd.MYOV · Entity 115677 | Director | August 31, 2018 | September 04, 2018 |
| Sio Gene Therapies Inc.AXON · Entity 130622 | Pres (ASG) & Chief Comm. Ofc. | March 15, 2018 | March 16, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alector, Inc.
Report date June 17, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 98,650 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 28,700 · Balance 98,650 F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 17, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2036-06-16 | Direct | 9,450 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 9,450 · Balance 9,450 F2: The shares subject to the option vest in 12 equal monthly installments beginning on July 17, 2026, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 17, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.
F2: The shares subject to the option vest in 12 equal monthly installments beginning on July 17, 2026, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders.
Myovant Sciences Ltd.
Report date August 31, 2018 · Filed September 04, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.25 · Expires 2028-08-30 | Direct | 22,500 |
Reported balance
After 2018-08-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-08-31 · Grant · Acquired 22,500 · Balance 22,500 F1: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) August 31, 2019, and (b) the date that is one day prior to the Issuer's 2019 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) August 31, 2019, and (b) the date that is one day prior to the Issuer's 2019 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date.
Sio Gene Therapies Inc.
Report date March 15, 2018 · Filed March 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.46 · Expires 2028-03-15 | Direct | 340,000 |
Reported balance
After 2018-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-03-15 · Grant · Acquired 340,000 · Balance 340,000 F1: The option vests over a period of four years, with one quarter of the common shares underlying the option vesting on March 15, 2019 and the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. F2: The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.46 · Expires 2028-03-15 | Direct | 100,000 |
Reported balance
After 2018-03-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-15 · Grant · Acquired 100,000 · Balance 100,000 F2: The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. F3: One-third of the option will vest at such time as the Issuer's stock price is equal to $4.38; one-third of the option will vest at such time as the Issuer's stock price is equal to $7.30, and one-third of the option will vest at such time as the Issuer's stock price is equal to $10.22, in each case subject to the Reporting Person providing continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests over a period of four years, with one quarter of the common shares underlying the option vesting on March 15, 2019 and the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.
F2: The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.
F3: One-third of the option will vest at such time as the Issuer's stock price is equal to $4.38; one-third of the option will vest at such time as the Issuer's stock price is equal to $7.30, and one-third of the option will vest at such time as the Issuer's stock price is equal to $10.22, in each case subject to the Reporting Person providing continuous service to the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 17, 2026 20:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantStock Option (right to buy) · Derivative | 9,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-274124 · ownership.xml · derivative · entry 2 Altmeyer Mark · CIK 0001643074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,450 Underlying: Common Stock · 9,450 shares Expires 2036-06-16 F2 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on July 17, 2026, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 17, 2026 Filed Jun 17, 2026 20:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 28,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-274124 · ownership.xml · nonDerivative · entry 1 Altmeyer Mark · CIK 0001643074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,650 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 17, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 22:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantStock Option (right to buy) · Derivative | 9,450 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0000950170-25-085614 · ownership.xml · derivative · entry 2 Altmeyer Mark · CIK 0001643074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,450 Underlying: Common Stock · 9,450 shares Expires 2035-06-10 F2 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on July 11, 2025, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 22:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 28,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-085614 · ownership.xml · nonDerivative · entry 1 Altmeyer Mark · CIK 0001643074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,950 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 11, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 21:01 UTC | Alector, Inc. ALEC · Entity 6051 | GrantStock Option (right to buy) · Derivative | 19,420 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0000950170-24-034849 · ownership.xml · derivative · entry 2 Altmeyer Mark · CIK 0001643074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,420 Underlying: Common Stock · 19,420 shares Expires 2034-03-19 F2 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on April 19, 2024. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 21:01 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 41,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-034849 · ownership.xml · nonDerivative · entry 1 Altmeyer Mark · CIK 0001643074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,250 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in 12 equal quarterly installments beginning on September 1, 2024. Read SEC document |
| August 31, 2018 Filed Sep 4, 2018 20:44 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $24.25 | $0.00 |
DisclosureSEC source: 0001209191-18-049222 · doc4.xml · derivative · entry 1 Altmeyer Mark · CIK 0001643074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Shares · 22,500 shares Expires 2028-08-30 F1 · derivative.exercise_date: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) August 31, 2019, and (b) the date that is one day prior to the Issuer's 2019 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:32 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001209191-18-020365 · doc4.xml · derivative · entry 2 Altmeyer Mark · CIK 0001643074 · Pres (ASG) & Chief Comm. Ofc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2028-03-15 F2 · derivative.exercise_date: The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. F3 · derivative.exercise_date: One-third of the option will vest at such time as the Issuer's stock price is equal to $4.38; one-third of the option will vest at such time as the Issuer's stock price is equal to $7.30, and one-third of the option will vest at such time as the Issuer's stock price is equal to $10.22, in each case subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:32 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | GrantEmployee Stock Option (Right to Buy) · Derivative | 340,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001209191-18-020365 · doc4.xml · derivative · entry 1 Altmeyer Mark · CIK 0001643074 · Pres (ASG) & Chief Comm. Ofc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,000 Underlying: Common Shares · 340,000 shares Expires 2028-03-15 F1 · derivative.exercise_date: The option vests over a period of four years, with one quarter of the common shares underlying the option vesting on March 15, 2019 and the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. F2 · derivative.exercise_date: The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. Read SEC document |
| November 17, 2017 Filed Jun 15, 2018 21:20 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Shares | 3,500 | $13.38 | $46,830.00 |
DisclosureSEC source: 0001209191-18-038121 · doc4.xml · nonDerivative · entry 1 Altmeyer Mark · CIK 0001643074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Read SEC document |
| August 18, 2017 Filed Oct 20, 2017 20:45 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $13.14 | $0.00 |
DisclosureSEC source: 0001209191-17-057643 · doc4.xml · derivative · entry 1 Altmeyer Mark · CIK 0001643074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Shares · 22,500 shares Expires 2027-08-17 F1 · derivative.exercise_date: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) August 18, 2018, and (b) the date that is one day prior to the Issuer's 2018 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:18 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 11,154 | $0.00 Strike: $12.68 | $0.00 |
DisclosureSEC source: 0001209191-17-033261 · doc4.xml · derivative · entry 1 Altmeyer Mark · CIK 0001643074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,154 Underlying: Common Shares · 11,154 shares Expires 2027-05-14 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option vest and become exercisable on May 15, 2018; the balance of the shares vest and become exercisable in a series of eight (8) successive equal quarterly installments measured from May 15, 2018, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| April 28, 2017 Filed May 3, 2017 00:59 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $24.24 | $0.00 |
DisclosureSEC source: 0001209191-17-029469 · doc4.xml · derivative · entry 1 Altmeyer Mark · CIK 0001643074 · Pres (ASG) & Chief Comm. Ofc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2027-04-28 F1 · derivative.exercise_date: This option vests over a period of four years, with one quarter of the common shares underlying the option vesting on April 28, 2018 and the remainder vesting in twelve equal quarterly installments thereafter. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. F2 · balance_after: Includes only options with the same termination date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.